BPC-157 vs TB-500

BPC-157 and TB-500 are the two peptides most often discussed in preclinical tissue-repair research, and they are frequently mentioned in the same breath. They are, however, quite different molecules with different origins and different proposed mechanisms.

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence found in a protein in gastric juice. TB-500 is a synthetic peptide modeled on the active, actin-binding region of thymosin beta-4, a protein present in most cells. Research on BPC-157 has tended to focus on angiogenesis, nitric oxide signaling and gastrointestinal models, while research on thymosin beta-4 and TB-500 has centered on actin regulation and cell migration. Neither is an approved medicine in the US; both are research compounds. This page compares their structure, mechanisms studied, research areas and lab handling so you can decide which fits your research question. PRIME supplies both for laboratory research use only.

BPC-157: the gastric-derived peptide

BPC-157, short for body protection compound 157, is a synthetic peptide of 15 amino acids. Its sequence is derived from a larger protein found in gastric juice, and it is notable among research peptides for its reported stability, which has made it a common subject in oral and gastrointestinal models as well as other animal models.

Most BPC-157 research is preclinical, carried out in rodent models and cell systems. The mechanisms that have been investigated include the formation of new blood vessels (angiogenesis), interactions with the nitric oxide system, and changes in the expression of growth factor receptors involved in tissue repair. Research areas include:

• Tendon and ligament injury models
• Muscle injury models
• Gastrointestinal lining and ulcer models
• Skin wound models
• Blood vessel formation and vascular signaling

BPC-157 is a research compound and is not an approved medicine in the US. Human data are very limited, so conclusions drawn from animal work should not be extended beyond the models in which they were observed.

PRIME supplies BPC-157 as a lyophilized powder for in-vitro and preclinical research. It is sold for laboratory research use only and is not for human consumption.

TB-500: the thymosin beta-4 fragment

TB-500 is a synthetic peptide modeled on the active region of thymosin beta-4, a naturally occurring protein found in nearly all human and animal cells. Thymosin beta-4 is one of the main proteins that binds and sequesters G-actin, the building block of the actin cytoskeleton, and in doing so it helps regulate how cells change shape and move.

TB-500 research builds on that biology. Because the actin-binding region is thought to carry much of thymosin beta-4's activity, the shorter synthetic peptide is used to study those functions in a more convenient form. Mechanisms and areas that have been investigated, largely for thymosin beta-4 and in preclinical models, include:

• Cell migration and actin cytoskeleton dynamics
• Skin and corneal wound models
• Cardiac tissue models
• Muscle and connective tissue models
• Inflammatory signaling in tissue repair

An important caveat is that much of the published literature concerns full-length thymosin beta-4 rather than TB-500 specifically, so results should not be assumed to transfer automatically. TB-500 is a research compound and is not an approved medicine in the US.

PRIME supplies TB-500 as a lyophilized powder for in-vitro and preclinical research. It is sold for laboratory research use only and is not for human consumption.

The two peptides point toward different mechanisms, so the research question should drive the choice. Both have been studied mostly in animal and cell models, so either one suits preclinical work rather than questions that depend on human data.

BPC-157 fits studies centered on angiogenesis, nitric oxide signaling, gastrointestinal models, or tendon and ligament models, where most of its preclinical literature sits. Its reported stability also makes it a frequent choice for gastrointestinal model work.

TB-500 fits studies centered on actin dynamics, cell migration and wound models, or work that builds on the thymosin beta-4 literature. It is the more natural choice when the cytoskeleton is the focus.

Because their proposed mechanisms differ, some study designs examine the two together; the BPC-157 and TB-500 blend guide covers that combination. For each compound on its own, see the BPC-157 research guide and the TB-500 research guide. Every batch has a published certificate of analysis on the lab results page.

For laboratory research use only. Not for human consumption.